Compare Apple Inc (AAPL) vs Viatris Inc (VTRS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Viatris Inc — how do they compare? Apple Inc trades at $313.2 (market cap $4.56T), while Viatris Inc trades at $16.6 (market cap $19.75B). The key difference: Apple Inc is far larger — about 230.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| AAPL | VTRS | |
|---|---|---|
Market Cap | $4.56T | $19.75B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $17.39 |
52-Week Low | $202.38 | $8.74 |
Enterprise Value | $4.58T | $31.96B |
Dividend Yield | 0.35% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.27, up 0.2% today, with a bullish technical outlook and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $416.16B and net income of $112.01B, though valuation ratios like P/E of 37.61 are elevated. Recent news highlights AI integration via Alphabet's Gemini and ongoing retail adjustments, including store closures amid union disputes.
Outlook remains positive with analyst consensus targeting $329.62, but risks include high valuation sensitivity and competitive pressures. Earnings have consistently beaten estimates, supporting growth potential, yet investors should monitor margin pressures and regulatory scrutiny in key markets.
Viatris (VTRS) trades at $16.96, up 1.56% on the day and near its 52-week high of $17.53. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. However, fundamentals reveal challenges, including a net loss of $3.51 billion in 2025 and negative profit margins, though revenue remains stable around $14.3 billion. Positive developments include a strong pipeline, with recent FDA acceptance of a new drug application for fast-acting meloxicam and positive Phase 3 results for VR-205.
The outlook is mixed; analyst consensus is a 'Hold' with a $20 price target, suggesting modest upside. Key opportunities lie in pipeline catalysts and debt reduction, but risks include persistent profitability issues, high debt levels, and competitive pressures. The stock's valuation metrics like P/S of 1.35 may appeal to value investors, but earnings sustainability is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
